Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALAP-1 (marketed as Aller-7) is a proprietary polyherbal formulation developed for the management of seasonal allergic rhinitis. It consists of extracts from seven medicinal plants: *Phyllanthus emblica* (Amla), *Terminalia chebula* (Chebulic Myrobalan), *Terminalia bellerica* (Belleric Myrobalan), *Albizia lebbeck*, *Zingiber officinale* (Ginger), *Piper nigrum* (Black Pepper), and *Piper longum* (Long Pepper). The formulation exhibits multi-target activity, including antihistaminic, anti-inflammatory, and mast cell stabilizing properties. Specifically, it has been shown to inhibit the release of histamine from mast cells and suppress the 5-lipoxygenase (5-LOX) pathway, thereby reducing the production of leukotrienes. Clinical studies, including randomized, double-blind, placebo-controlled trials, have evaluated its efficacy in attenuating nasal symptoms and histamine-induced nasal provocation in patients with seasonal allergic rhinitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ALAP-1.